Skip to content

Citius Oncology, Inc. CTOR Increase (Decrease) in Prepaid Expense

Increase (Decrease) in Prepaid Expense at other companies

OS Therapies logo
OS TherapiesOSTX
-$63.08K
Robinhood Markets, Inc. logo
Robinhood Markets, Inc.HOOD
$54M+315%
Dine Brands Global logo
Dine Brands GlobalDIN
-$5.4M-92.9%
JAC
Jackson Acquisition Company IIJACS
$21.18K-39.0%
NMP
Nuveen Prem Inc Muni FundNMP
$34.85K+359%
MGP Ingredients logo
MGP IngredientsMGPI
$3.67M+258%

Other financials

Income statement

See full
Revenue$1.7M
Gross profit$1.3M
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation

See full
Market cap$60.45M-74.7%

Returns & leverage

See full
Return on equity-119.9%+46.7pp
Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidExpense.

The official record: Citius Oncology, Inc.’s 10-Q, filed February 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s increase (decrease) in prepaid expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Citius Oncology, Inc.'s increase (decrease) in prepaid expense?
Citius Oncology, Inc. (CTOR) reported increase (decrease) in prepaid expense of $1.83M in Q4 2025.